OXFORD, UK - Oxford BioDynamics Plc (AIM: OBD), a biotechnology company, has announced the successful outcomes of a clinical study for its EpiSwitch® Colorectal No-Stool Test (NST), which has been ...

Researchers from The Institute of Cancer Research in London have developed a new test that can predict colorectal cancer risk ...

"Right now lots of people are coming to the hospital with respiratory tract infections and we don't know whether it's viral ...

All three were hooked up to machines that provided a readout of their vital signs, and all three were prepared to have a syringe of manufactured blood injected into their veins. There were, of course, ...